Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.

@article{Valgimigli2010TirofibanAA,
  title={Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.},
  author={Marco Valgimigli and Giuseppe Biondi-Zoccai and Matteo Tebaldi and Arnoud W. J. van’t Hof and Gianluca Campo and Christian Hamm and Jurri{\"e}n Maria ten Berg and Leonardo Bolognese and Francesco Saia and Gian Battista Danzi and Carlo Briguori and Ertan Okmen and Spencer B. King and David J Moliterno and Eric J. Topol},
  journal={European heart journal},
  year={2010},
  volume={31 1},
  pages={
          35-49
        }
}
  • Marco Valgimigli, Giuseppe Biondi-Zoccai, +12 authors Eric J. Topol
  • Published in European heart journal 2010
  • Medicine
  • AIMS To perform a thorough and updated systematic review of randomized clinical trials comparing tirofiban vs. placebo or vs. abciximab. METHODS AND RESULTS We searched for randomized trials comparing tirofiban vs. placebo or any active control. Odds ratios (OR) were computed from individual studies and pooled with random-effect methods. Thirty-one studies were identified involving 20,006 patients (12 874 comparing tirofiban vs. heparin plus placebo or bivalirudin alone, and 7132 vs… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 59 CITATIONS, ESTIMATED 24% COVERAGE

    The Safety and Efficacy of 12 Versus 24 Hours of Tirofiban Infusion in Patients Undergoing Primary Percutaneous Coronary Intervention

    • Selim Topçu, Huseyin Karal, +6 authors Serdar Sevimli
    • Medicine
    • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    • 2015
    VIEW 6 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Triple Antiplatelet Therapy in Acute Coronary Syndromes

    VIEW 18 EXCERPTS
    CITES METHODS & BACKGROUND

    FILTER CITATIONS BY YEAR

    2010
    2020

    CITATION STATISTICS

    • 3 Highly Influenced Citations

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 50 REFERENCES

    Main results of the tailoring treatment with tirofiban in patients showing resistance to aspirin or resistance to clopidogrel study (3T/2R)

    • M. Valgimigli
    • 2008

    NAPLES: a prospective, randomized trial comparison of bivalirudin and unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention

    • C. Briguori
    • 2008